Cytogenetic and loss-of-heterozygosity (LOH) studies have demonstrated that deletions of the chromosome 3 short arm (3p) occur at very high frequency in all forms of lung cancer (universal loss in SCLC AND about-80% in NSCLC). These observation suggest that 3p encodes one or more tumor suppressor genes whose loss is critical to lung cancer development and progression. Data from our laboratory and others have demonstrated 4 separate, recurring homozygous deletion regions on 3p. Project 1 will investigate the role of 3p loss in lung cancer and pre-malignant lesions. A primary goal of t his project is the translation of our experimental results into clinically useful approaches. While the most sensitive diagnostic 3p reagents will come from the actual target genes, a major advance in both LOH and FISH detection will result, respectively, from the use of highly polymorphic PCR-based markers and hybridization probes closely representing the target gene regions. To accomplish this, we will precisely define the affected 3p intervals and develop additional corresponding polymorphic markers and FSH probes that will be applied to the analysis of tumors, dysplastic biopsies and sputa. Not only will these reagents provide a powerful means for detecting small 3p alterations in diagnostic sample but they will facilitate the molecular cloning of target genes through improved definition of critical regions. B working with a common set of samples, we will be able to correlate our 3p results with those of other SPORE members and inter-SPORE collaborators investigating chr 9, p53, RB, p16INK4, cyclin D1 and other chromosomal loci frequently affected in lung cancer. From these combined data, we hope to gain a comprehensive understanding of genetic changes which characterize each type of lung cancer or pre-neoplastic lesion, and to begin to address issues of prognosis and predictability. We will further characterize and conduct gene searches within two selected target regions (distal 3p21.3 and 3p12(13) that undergo recurrent homozygous deletion as well as well as perform functional assays of candidate tumor suppressor genes. This latter effort will include transfection experiments of candidate genes into lung cancer cell lines to determine their effect on growth and tumorigenesis. Lastly, we will identify the region of chromosome 3 which encodes a recently recognized inhibitor of telomerase activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-08
Application #
6367950
Study Section
Project Start
2000-05-01
Project End
2003-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
8
Fiscal Year
2000
Total Cost
$156,688
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Ravichandran, Kameswaran; Holditch, Sara; Brown, Carolyn N et al. (2018) IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol 314:F356-F366
Hilberg, Frank; Tontsch-Grunt, Ulrike; Baum, Anke et al. (2018) Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases. J Pharmacol Exp Ther 364:494-503
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
DeHart, David N; Fang, Diana; Heslop, Kareem et al. (2018) Opening of voltage dependent anion channels promotes reactive oxygen species generation, mitochondrial dysfunction and cell death in cancer cells. Biochem Pharmacol 148:155-162
Patil, Tejas; Smith, Derek E; Bunn, Paul A et al. (2018) The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol 13:1717-1726
Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507
Helfrich, Barbara A; Gao, Dexiang; Bunn Jr, Paul A (2018) Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy. Lung Cancer 118:148-154
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 435 publications